QuestionSBA
QuestionChoice
This is incorrect. It is diltiazem which inhibits cytochrome P3A4, not simvastatin. This results in a rise in simvastatin levels which can result in pathological muscle breakdown and eventually rhabdomyolysis.
10026336
b
Simvastatin inhibits cytochrome P3A4 which causes a rise in diltiazem
QuestionChoice
This is incorrect. Diltiazem inhibits cytochrome P3A4, the enzyme responsible for breaking down simvastatin. This results in a rise in simvastatin levels which can result in pathological muscle breakdown and eventually rhabdomyolysis.
10026337
c
Diltiazem activates cytochrome P3A4 which causes a rise in simvastatin
QuestionChoice
This is incorrect. Diltiazem inhibits cytochrome P3A4, the enzyme responsible for breaking down simvastatin. This results in a rise in simvastatin levels which can result in pathological muscle breakdown and eventually rhabdomyolysis.
10026339
e
Both drugs are broken down by the same enzyme and hence concurrent use causes elevation in levels of both
QuestionChoice
This is correct. Diltiazem inhibits cytochrome P3A4, the enzyme responsible for breaking down simvastatin. This results in a rise in simvastatin levels which can result in pathological muscle breakdown and eventually rhabdomyolysis.
10026335
a
Diltiazem inhibits cytochrome P3A4 which causes a rise in simvastatin levels
QuestionChoice
This is incorrect. Diltiazem inhibits cytochrome P3A4, the enzyme responsible for breaking down simvastatin. This results in a rise in simvastatin levels which can result in pathological muscle breakdown and eventually rhabdomyolysis.
10026338
d
Simvastain activates cytochrome P3A4 which causes a rise in diltiazem
Concept
Chapter
2693
5888
Rhabdomyolysis
Topic
133
Endocrinology
17665
Why does the concurrent use of simvastatin and diltiazem increase the risk of rhabdomyolysis?
a